Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)

Blood

Volumn 102, Issue 6, 2003, Pages 2236-2239

  Wohlbold, Lara ^b   Van der Kuip, Heiko ^b   Miething, Cornelius ^b   Vornlocher, Hans Peter ^b   Knabbe, Cornelius ^b   Duyster, Justus ^b   Aulitzky, Walter E ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; LIPOCORTIN 5; PROTEIN TYROSINE KINASE INHIBITOR; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG SENSITIVITY; GAMMA IRRADIATION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; RNA SEQUENCE; WESTERN BLOTTING;

EID: 0141790842     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-12-3899     Document Type: Article

References (26)

1. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A. 1990;87:6649-6653.
2. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998;92: 3780-3792.
3. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
4. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
5. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
6. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
7. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
8. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.
9. Hochhaus A, Kreil S, Crobin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001;293:2163.
10. Shah NP, Nicoll JM, Gorre ME, Paquette RL, Ford J. Resistence to Gleevec: sequence analysis reveals a spectrum of Bcr/ABL kinase domain mutations in both acquired- and de novo resistance cases of chronic myelogenous leukemia (CML) in myeloid blast crisis [abstract]. Blood. 2001;98:770.
11. Skorski T, Nieborowska-Skorska M, Nicolaides NC, et al. Suppression of Philadelphia 1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1994;91:4504-4508.
12. Smetsers TF, Skorski T, van der Locht LT, et al. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia. 1994;8:129-140.
13. Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci U S A. 2001;98:9742-9747.
14. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21 - and 22-nucleotide RNAs. Genes Dev. 2001;15:188-200.
15. Michael T, Sharp M, Sharp PA. Gene silencing in mammals by small interference RNAs. Nat Rev Genet. 2002;3:737-747.
16. Scherr M, Blattmer K, Winkler T, Heidenreich O, Ganser A, Eder M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood. 2003;101:1566-1569.
17. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998;92: 3780-3792.
18. Bai RY, Ouyang T, Miething C, et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood. 2000;96:4319-4327.
19. Oetzel C, Jonuleit T, Götz AW, et al. The tyrosine kinase inhibitor CG P 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res. 2000;6:1958-1968.
20. van der Kuip H, Goetz AW, Miething C, Duyster J, Auiitzky WE. Adhesion to fibronectin selectivly protects Bcr-Abl+ cells from DNA damage induced apoptoses. Blood. 2001;98:1532-1541.
21. Goetz AW, van der Kuip H, Maya R, Oren M, Aulitzky WE. Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells. Cancer Res. 2001;61:7635-7641.
22. Horita M, Andreu EJ, Benito A, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000;191:977-984.
23. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood. 2000;96:2269-2276.
24. Jonuleit T, van der Kuip H, Miething C, et al. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood. 2000;96:1933-1939.
25. Wilda M, Fuchs U, Wössmann W, Borkhardt A. Killing leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene. 2002;21: 5716-5724.
26. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117-125.